In an effort to improve current leukaemia therapies our observations may suggest that CaSR antagonism by calcilytics, which are being investigated for their anabolic effects in osteoporosis, hypocalcaemia or hypercalciuria49, may be beneficial as complementary treatment in AML. The gene discussed is CASR; the disease is Hypocalcemia.